



Statement of compliance with Regulation (EU) 2016/679 (GDPR)

Sponsor	Sutro Biopharma, Inc.
Title of the clinical trial	REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator's Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
EU CT Number	2023-506196-10-00

The processing of clinical trials may include personal data. Any processing is based on the provisions of binding legal regulations, specifically:

REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)

REGULATION (EU) 2018/1725 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 23 October 2018 on the protection of natural persons with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC

REGULATION (EU) NO 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC

Sutro Biopharma, Inc. has designed, implemented, and monitors the effectiveness of a data protection compliance program intended to ensure compliance with Regulation (EU) 2016/679 known as the General Data Protection Regulation (GDPR). Sutro Biopharma, Inc. confirms that collection and processing during clinical trials is done in full compliance with the European Regulation 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (GDPR).

To the best of our knowledge, Sutro Biopharma, Inc. is compliant with that data protection compliance program and has implemented adequate technical and organisational measures to meet any relevant obligations that apply to Sutro Biopharma, Inc. under GDPR and applicable national data protection laws.

DocuSigned by:

 44336B44EE0F499

Print Name: David Pauling
 Title: General Counsel
 Sutro Biopharma, Inc.

1/12/2024

Date (DD/MMM/YYYY)